Australia

Myrio Therapeutics Announces Collaboration with Leading Research Institutions to Advance Solid Tumor T cell Immunotherapeutics

* Myrio Therapeutics, the University of Pennsylvania Perelman School of Medicine, and NYU Langone Health have entered a research collaboration to accelerate the development of next-generation T cell immunotherapies * Partnership with T cell experts Daniel J Powell Jr., PhD, and Mark Yarmarkov...

2025-10-28 19:35 1939

Kazia Therapeutics to Request FDA Type C Meeting to Discuss Overall Survival Data in GBM and Potential NDA Filing in Alignment with FDA initiative Project FrontRunner

SYDNEY, Oct. 27, 2025 /PRNewswire/ -- Kazia Therapeutics Limited ("Kazia" or the "Company") today announced its intention to request and hold a follow-up Type C meeting with the U.S. Food & Drug Administration (FDA) to discuss overall survival (OS) findings in newly diagnosed glioblastoma (GBM) p...

2025-10-27 19:15 2344

Clarity signs copper-67 Supply Agreement with Nusano

SYDNEY, Oct. 16, 2025 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity" or "Company"), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for patients with cancer, is pleased to announce the signing of a Supp...

2025-10-16 21:04 3966

SK bioscience Files for First-in-Human Trial of Universal Coronavirus Vaccine (Pan-sarbecovirus Vaccine) GBP511 Phase 1/2 study in Australia

* Candidate designed to protect against COVID-19 variants and broader Sarbecoviruses * Phase 1/2 study to enroll ~500 healthy adults, with topline results expected by 2028 * We aim to build a universal Sarbecovirus vaccine platform to proactively address future pandemics SEONGNAM, South Kor...

2025-10-15 20:00 3746

Co-PSMA trial achieves primary endpoint

SYDNEY, Oct. 14, 2025 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity" or "Company"), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for patients with cancer, is pleased to announce that the Co-PSMA (NCT...

2025-10-14 21:03 3819

Locksley Announces Major Advancement at Mojave as Structural Mapping Expands Scale of Antimony Target with a 400% Increase in Target Strike Length

SAN BERNARDINO, Calif., Oct. 10, 2025 /PRNewswire/ -- Locksley Resources, Ltd. (ASX: LKY; OTCQX: LKYRYF) announced that recent structural mapping has significantly expanded the scale of its target mineralized corridor at the Desert Antimony Mine (DAM) Prospect. A new parallel structural target wa...

2025-10-10 20:35 4009

Locksley Reports High-Grade Antimony Concentrate at Significantly Higher Grades than Comparable American Projects in Initial Metallurgical Test Work of Surface Samples from the Company's Desert Antimony Mine Project in California

SAN BERNARDINO, Calif., Oct. 8, 2025 /PRNewswire/ -- Locksley Resources, (ASX: LKY; OTCQB: LKYRF) announced that the company's advancing metallurgical test work program being conducted on surface samples collected from the Desert Antimony Mine (DAM) Prospect at the company's project in the Mojave...

2025-10-08 20:40 2717

Kazia Therapeutics Announces Collaboration and In-Licensing Agreement for First-in-Class PD-L1 Protein Degrader Program

SYDNEY, Oct. 7, 2025 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused drug development company, today announced an exclusive collaboration and in-licensing agreement (the "Agreement") with QIMR Berghofer for a first-in-class PD-L1 degrader program. The lead optimized...

2025-10-07 20:30 2518

FDA Lifts Clinical Hold on NUZ-001

Highlights: * U.S. FDA lifts the Clinical Hold on NUZ‑001, Neurizon®'s lead investigational therapy for ALS * Clears the way for entry into the HEALEY ALS Platform Trial expected to commence in Q4 CY2025 * IND supported by robust preclinical safety data and comprehensive manufacturing and ...

2025-10-06 14:06 3005

ISX Financial EU Plc Reports Profitable Growth and Strong Capital Position in H1 2025

NICOSIA, Cyprus, Oct. 3, 2025 /PRNewswire/ -- ISX Financial EU Plc (ISXX), a leading provider of regulated transactional banking and real-time payment solutions, today announced its unaudited H1 2025 financial results for the six months ended30 June 2025. ISXX delivered profitable growth, improve...

2025-10-03 21:47 2762

EVOLVE MVMT Launches Wearable to Track Shock Absorption for Runners

Revolutionary running tech offers real-time insights into step quality, injury risk, and performance. BYRON BAY, Australia, Sept. 30, 2025 /PRNewswire/ -- EVOLVE MVMT has launched the world's first wearable designed specifically to measure shock absorption and step quality for runners on Kicksta...

2025-09-30 21:00 1819

Lumonus Announces Transformative Multi-Year Licensing Agreement with Smarter Radiation Oncology® to bring evidenced-based directives to U.S. cancer centers

NEW YORK and SYDNEY, Sept. 29, 2025 /PRNewswire/ -- Lumonus , a healthcare technology company transforming cancer care with its AI-powered platform, today announced a multi-year agreement with Smarter Radiation Oncology® (SRO), a company incubated by Northwell Health. T...

2025-09-30 00:00 1891

Locksley Names Industry Veterans CEO and COO to Fast-Track its US Mine-to-Market Effort

SAN BERNARDINO, Calif., Sept. 25, 2025 /PRNewswire/ -- Locksley Resources Limited (ASX: LKY; OTCQB: LKYRF) announced the appointment ofKerrie Matthews as Chief Executive Officer (CEO) andDanny George as Chief Operating Officer (COO) of the company. The appointments are newly-created positions and...

2025-09-25 20:20 3614

Locksley Continues to Strengthen its Position in Paving Pathway to 100% Made in America

Company Reports Exceptional Initial Metallurgical Results for Its US Mojave Project SAN BERNARDINO, Calif, Sept. 22, 2025 /PRNewswire/ -- Locksley Resources Ltd. (ASX: LKY; OTCQB: LKYRF) announced it has achieved significant results from initial metallurgical testwork completed by the company on...

2025-09-22 20:10 3607

Aduna Welcomes Spark as First New Zealand Partner

PLANO, Texas, Sept. 17, 2025 /PRNewswire/ -- Aduna , the global aggregator of standardized network APIs, today announced a partnership with Spark,New Zealand's leading digital services provider, to accelerate the adoption of advanced network APIs across the country. With...

2025-09-17 11:44 2359

/DISREGARD RELEASE: GIM Trading/

Journalists and other readers should disregard the news release, GIM Trading Unveils Commitment to Long-Term Investment Solutions Amid Shifts in Australian Economic Landscape, issued28-May-2024 over PR Newswire. ...

2025-09-17 08:49 2092

ZERO LATENCY VR INVITES YOU IN, BUT SOMETHING WON'T LET YOU LEAVE - HAUNTED IS COMING

Something horrifying is here. You are not safe. You need to get out. RUN. MELBOURNE, Australia, Sept. 15, 2025 /PRNewswire/ -- Zero Latency VR , the undisputed leader in immersive entertainment and the mastermind behind the largest true location-based free-roam VR netw...

2025-09-16 05:30 3666

Locksley Resources Announces Significant Expansion of its Exploration Program for both Rare Earths and Antimony After Increasing its Landholding to More than 40 Square Kilometers in California's Mojave Region

SAN BERNARDINO, Calif., Sept. 15, 2025 /PRNewswire/ -- Locksley Resources Ltd. (ASX: LKY; OTCQB: LKYRF) announced it will significantly expand its exploration program at its significantly increased landholding in the Mojave Desert. Earlier this month the company announced the addition of 249 addi...

2025-09-15 20:35 5638

Zeki Data Launches Company Diagnostics to Expose Hidden Risks in Deep-Tech Firms

LONDON, Sept. 11, 2025 /PRNewswire/ -- Zeki Data , the UK-based deep-tech intelligence firm, today unveiledCompany Diagnostics , a breakthrough tool that reveals organisational health and hidden risks inside deep-tech companies—far...

2025-09-11 20:21 2244

Kazia Therapeutics Reports Complete Ex Vivo Disruption of Large Circulating Tumor Cell Clusters in Stage IV HER2-Positive Breast Cancer with Paxalisib Monotherapy

SYDNEY, Sept. 11, 2025 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused drug development company, today announced new findings from a collaborative research program led by ProfessorSudha Rao at QIMR Berghofer. In this ex vivo study, blood samples from Stage IV HER2-...

2025-09-11 20:00 3433
1234567 ... 45